Literature DB >> 18035318

Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.

Dimitar G Efremov1, Stefania Gobessi, Pablo G Longo.   

Abstract

Several features of the B-cell receptor (BCR) have emerged as major prognostic factors in chronic lymphocytic leukemia (CLL). In particular, the absence of somatic mutations in the immunoglobulin variable region genes and expression of the protein tyrosine kinase ZAP-70 are strongly associated with an aggressive clinical course, and both features have been correlated with a greater capacity of the BCR to transmit antigen-induced signals. Additionally, differences in BCR structure and reactivity indicate that CLL B-cells from the two prognostic subsets may recognize different types of antigens. Antigens that are not rapidly internalized induce sustained BCR signaling that can promote the survival of the leukemic B-cells. The BCR signal is initially transmitted by the Syk kinase and modulated by ZAP-70, which shows inefficient or absent tyrosine kinase activation in B-cells. However, both ZAP-70 expression and sustained BCR engagement have been associated with prolonged activation of the Akt and ERK kinases, which is required for the induction of several antiapoptotic proteins, including Mcl-1, Bcl-xL and XIAP. Therefore, targeting components along the BCR signaling pathway may be a promising strategy for the treatment of CLL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035318     DOI: 10.1016/j.autrev.2007.02.021

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  31 in total

Review 1.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

2.  Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.

Authors:  Roberto Negro; Stefania Gobessi; Pablo G Longo; Yantao He; Zhong-Yin Zhang; Luca Laurenti; Dimitar G Efremov
Journal:  Blood       Date:  2012-05-08       Impact factor: 22.113

Review 3.  Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.

Authors:  Ting-Ting Han; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

Review 4.  Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.

Authors:  Rajendra N Damle; Carlo Calissano; Nicholas Chiorazzi
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

5.  Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells.

Authors:  Elayne Hondares; Mark Adrian Brown; Boris Musset; Deri Morgan; Vladimir V Cherny; Christina Taubert; Mandeep K Bhamrah; David Coe; Federica Marelli-Berg; John G Gribben; Martin J S Dyer; Thomas E DeCoursey; Melania Capasso
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-25       Impact factor: 11.205

6.  FcγRIIb expression in early stage chronic lymphocytic leukemia.

Authors:  Rosa Bosch; Alba Mora; Eva Puy Vicente; Gerardo Ferrer; Sonia Jansà; Rajendra Damle; Sergey Gorlatov; Kanti Rai; Emili Montserrat; Josep Nomdedeu; Marta Pratcorona; Laura Blanco; Silvana Saavedra; Ana Garrido; Albert Esquirol; Irene Garcia; Miquel Granell; Rodrigo Martino; Julio Delgado; Jorge Sierra; Nicholas Chiorazzi; Carol Moreno
Journal:  Leuk Lymphoma       Date:  2017-04-04

7.  Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

Authors:  Ryan M Young; Ian R Hardy; Raedun L Clarke; Nicolai Lundy; Polly Pine; Brian C Turner; Terry A Potter; Yosef Refaeli
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

8.  Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling.

Authors:  Shih-Shih Chen; Franak Batliwalla; Nichol E Holodick; Xiao-Jie Yan; Sophia Yancopoulos; Carlo M Croce; Thomas L Rothstein; Nicholas Chiorazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-02       Impact factor: 11.205

9.  MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Authors:  Bing Cui; Liguang Chen; Suping Zhang; Marek Mraz; Jessie-F Fecteau; Jian Yu; Emanuela M Ghia; Ling Zhang; Lei Bao; Laura Z Rassenti; Karen Messer; George A Calin; Carlo M Croce; Thomas J Kipps
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.